Monday's ETF with Unusual Volume: KBWP
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2025
0mins
Should l Buy WRB?
Source: NASDAQ.COM
ETF Performance Overview: The Invesco KBW Property & Casualty Insurance ETF saw significant trading activity on Monday, with American International Group down 0.3%, Hartford Financial Services flat, and W.R. Berkley up 1.7%. Siriuspoint lagged behind, trading lower by 1.8%.
Market Commentary: The opinions expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WRB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WRB
Wall Street analysts forecast WRB stock price to rise
12 Analyst Rating
2 Buy
7 Hold
3 Sell
Hold
Current: 71.650
Low
64.00
Averages
72.25
High
84.00
Current: 71.650
Low
64.00
Averages
72.25
High
84.00
About WRB
W. R. Berkley Corporation is an insurance holding company. It operates through two segments of the property casualty insurance business: Insurance and Reinsurance & Monoline Excess. Its Insurance businesses underwrite commercial insurance business, including excess and surplus lines, admitted lines and specialty personal lines throughout the United States, as well as insurance business in Asia, Australia, Canada, Continental Europe, Mexico, Scandinavia, South America and the United Kingdom. Its Insurance segment consists of business units, including Acadia Insurance, Admiral Insurance, Berkley Accident and Health, Berkley Agribusiness and others. It provides professional liability and casualty insurance for small to mid-sized businesses though the business unit Berkley Edge. Its Reinsurance & Monoline Excess offers reinsurance business on a facultative and treaty basis in the United States, United Kingdom, Continental Europe, Australia, the Asia-Pacific region and South Africa.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
W R Berkley Reports In-Line Q4 Earnings with Sales Beat
- Earnings Meet Expectations: W R Berkley reported Q4 earnings of $1.13 per share, aligning perfectly with analyst consensus, indicating stable profitability for the company.
- Sales Exceed Estimates: The company achieved quarterly sales of $3.721 billion, surpassing the analyst estimate of $3.661 billion, demonstrating strong market demand.
- Slight Stock Decline: Despite the solid performance, W R Berkley shares fell 0.4% to close at $63.83 on Monday, reflecting market caution regarding future growth.
- Analyst Target Adjustments: Analysts from BofA Securities and Mizuho lowered their price targets for W R Berkley from $69 to $66 and $67 respectively, indicating a conservative outlook on the company's future performance.
See More
Wall Street Analysts Adjust Ratings
- Acumen Price Target Raised: BTIG raised Acumen Pharmaceuticals' price target from $4 to $7, with analyst Thomas Shrader maintaining a Buy rating, indicating confidence in the company's growth potential despite a closing price of $2.08 on Monday.
- Exelixis Target Price Increase: HC Wainwright & Co. raised the price target for Exelixis from $49 to $52, with analyst Robert Burns maintaining a Buy rating, reflecting optimism about its market performance, closing at $43.61 on Monday.
- Baker Hughes Price Target Upgraded: BMO Capital increased Baker Hughes' price target from $55 to $65, with analyst Phillip Jungwirth maintaining an Outperform rating, suggesting a positive outlook on its future performance, closing at $56.29 on Monday.
- Brown & Brown Price Target Cut: B of A Securities lowered the price target for Brown & Brown from $94 to $90, with analyst Joshua Shanker maintaining a Neutral rating, indicating a cautious stance on the company's short-term performance, closing at $79.62 on Monday.
See More
Mixed U.S. Stock Futures as GM Earnings Draw Attention
- GM Earnings Expectations: Wall Street anticipates General Motors (GM) to report earnings of $2.20 per share and revenue of $45.80 billion before the market opens, with shares falling 0.5% to $79.05 in after-hours trading, indicating cautious market sentiment towards its performance.
- WR Berkley Steady Performance: W R Berkley reported fourth-quarter earnings of $1.13 per share, meeting analyst expectations, while sales reached $3.721 billion, exceeding the $3.661 billion forecast, leading to a 1.2% increase in shares to $67.71 in after-hours trading, reflecting market confidence in its sales growth.
- Boeing Earnings Preview: Analysts expect Boeing (BA) to report a quarterly loss of 39 cents per share on revenue of $22.47 billion before the market opens, with shares slightly rising 0.1% to $248.52 in after-hours trading, suggesting market optimism about its recovery prospects.
- Nucor's Disappointing Results: Nucor reported fourth-quarter earnings of $1.73 per share, missing the $1.91 estimate, and sales of $7.687 billion also fell short of the $7.868 billion expectation, causing shares to drop 3.1% to $172.13 in after-hours trading, reflecting market disappointment in its performance.
See More
W. R. Berkley Corporation Q4 2025 Earnings Highlights
- Record Operating Earnings: W. R. Berkley Corporation reported operating earnings of $450 million or $1.13 per share in Q4 2025, reflecting a 9.5% year-over-year growth, demonstrating the company's robust profitability amidst a competitive landscape.
- Significant Underwriting Income Growth: The company achieved a record pretax underwriting income of $338 million in the fourth quarter, up 14.9% from the previous year, indicating substantial progress in its underwriting operations and strengthening its market position.
- Capital Return Strategy: In Q4, the company returned $608 million of capital to investors, including $412 million in special and regular dividends and $196 million in share repurchases, showcasing effective capital management and commitment to shareholder returns.
- Technology Investment Outlook: Management plans to increase investments in technology and AI in 2026 and 2027, which is expected to enhance operational efficiency and generate significant returns in the coming years, further solidifying the company's competitive edge.
See More
W.R. Berkley Q4 Earnings Exceed Expectations
- Earnings Beat: W.R. Berkley's Q4 non-GAAP EPS of $1.13 surpasses expectations by $0.01, indicating strong profitability and market confidence in the company's performance.
- Revenue Growth: The company reported Q4 revenue of $3.72 billion, a 1.6% year-over-year increase, exceeding market expectations by $540 million, reflecting its competitive position and expanding customer base in the insurance market.
- Enhanced Capital Returns: The return on equity reached 21.4%, demonstrating effective capital utilization for high returns, while book value per share grew by 5.2%, consistently creating value for shareholders.
- Stable Combined Ratio: The accident year combined ratio before catastrophe losses stood at 87.9%, showcasing effective risk management and underwriting, despite a reported combined ratio of 89.4%, which remains within acceptable industry limits.
See More
U.S. Stock Futures Decline as Investors Await Earnings Reports
- Market Dynamics: U.S. stock futures fell on Monday, with major benchmark indices lower, reflecting investor caution ahead of earnings reports from companies like UnitedHealth, General Motors, and Microsoft.
- Earnings Expectations: Baker Hughes Co. rose 3.74% in premarket trading after reporting adjusted earnings of $0.78 per share for Q4, surpassing market estimates of $0.67, indicating strong performance in the energy sector.
- Stock Focus: Sarepta Therapeutics saw a 6.72% increase in its stock price after announcing the completion of its confirmatory trial commitment for ultra-rare disease PMO therapies, suggesting positive advancements in the biopharmaceutical field that may attract more investor interest.
- Economic Data Watch: Investors will closely monitor the Federal Reserve's interest rate decision this week, with markets pricing in a 97.2% likelihood of maintaining current rates, which could significantly impact both the stock and bond markets.
See More
W R Berkley Reports In-Line Q4 Earnings with Sales Beat
- Earnings Meet Expectations: W R Berkley reported Q4 earnings of $1.13 per share, aligning perfectly with analyst consensus, indicating stable profitability for the company.
- Sales Exceed Estimates: The company achieved quarterly sales of $3.721 billion, surpassing the analyst estimate of $3.661 billion, demonstrating strong market demand.
- Slight Stock Decline: Despite the solid performance, W R Berkley shares fell 0.4% to close at $63.83 on Monday, reflecting market caution regarding future growth.
- Analyst Target Adjustments: Analysts from BofA Securities and Mizuho lowered their price targets for W R Berkley from $69 to $66 and $67 respectively, indicating a conservative outlook on the company's future performance.
See More
Wall Street Analysts Adjust Ratings
- Acumen Price Target Raised: BTIG raised Acumen Pharmaceuticals' price target from $4 to $7, with analyst Thomas Shrader maintaining a Buy rating, indicating confidence in the company's growth potential despite a closing price of $2.08 on Monday.
- Exelixis Target Price Increase: HC Wainwright & Co. raised the price target for Exelixis from $49 to $52, with analyst Robert Burns maintaining a Buy rating, reflecting optimism about its market performance, closing at $43.61 on Monday.
- Baker Hughes Price Target Upgraded: BMO Capital increased Baker Hughes' price target from $55 to $65, with analyst Phillip Jungwirth maintaining an Outperform rating, suggesting a positive outlook on its future performance, closing at $56.29 on Monday.
- Brown & Brown Price Target Cut: B of A Securities lowered the price target for Brown & Brown from $94 to $90, with analyst Joshua Shanker maintaining a Neutral rating, indicating a cautious stance on the company's short-term performance, closing at $79.62 on Monday.
See More
Mixed U.S. Stock Futures as GM Earnings Draw Attention
- GM Earnings Expectations: Wall Street anticipates General Motors (GM) to report earnings of $2.20 per share and revenue of $45.80 billion before the market opens, with shares falling 0.5% to $79.05 in after-hours trading, indicating cautious market sentiment towards its performance.
- WR Berkley Steady Performance: W R Berkley reported fourth-quarter earnings of $1.13 per share, meeting analyst expectations, while sales reached $3.721 billion, exceeding the $3.661 billion forecast, leading to a 1.2% increase in shares to $67.71 in after-hours trading, reflecting market confidence in its sales growth.
- Boeing Earnings Preview: Analysts expect Boeing (BA) to report a quarterly loss of 39 cents per share on revenue of $22.47 billion before the market opens, with shares slightly rising 0.1% to $248.52 in after-hours trading, suggesting market optimism about its recovery prospects.
- Nucor's Disappointing Results: Nucor reported fourth-quarter earnings of $1.73 per share, missing the $1.91 estimate, and sales of $7.687 billion also fell short of the $7.868 billion expectation, causing shares to drop 3.1% to $172.13 in after-hours trading, reflecting market disappointment in its performance.
See More
W. R. Berkley Corporation Q4 2025 Earnings Highlights
- Record Operating Earnings: W. R. Berkley Corporation reported operating earnings of $450 million or $1.13 per share in Q4 2025, reflecting a 9.5% year-over-year growth, demonstrating the company's robust profitability amidst a competitive landscape.
- Significant Underwriting Income Growth: The company achieved a record pretax underwriting income of $338 million in the fourth quarter, up 14.9% from the previous year, indicating substantial progress in its underwriting operations and strengthening its market position.
- Capital Return Strategy: In Q4, the company returned $608 million of capital to investors, including $412 million in special and regular dividends and $196 million in share repurchases, showcasing effective capital management and commitment to shareholder returns.
- Technology Investment Outlook: Management plans to increase investments in technology and AI in 2026 and 2027, which is expected to enhance operational efficiency and generate significant returns in the coming years, further solidifying the company's competitive edge.
See More
W.R. Berkley Q4 Earnings Exceed Expectations
- Earnings Beat: W.R. Berkley's Q4 non-GAAP EPS of $1.13 surpasses expectations by $0.01, indicating strong profitability and market confidence in the company's performance.
- Revenue Growth: The company reported Q4 revenue of $3.72 billion, a 1.6% year-over-year increase, exceeding market expectations by $540 million, reflecting its competitive position and expanding customer base in the insurance market.
- Enhanced Capital Returns: The return on equity reached 21.4%, demonstrating effective capital utilization for high returns, while book value per share grew by 5.2%, consistently creating value for shareholders.
- Stable Combined Ratio: The accident year combined ratio before catastrophe losses stood at 87.9%, showcasing effective risk management and underwriting, despite a reported combined ratio of 89.4%, which remains within acceptable industry limits.
See More
U.S. Stock Futures Decline as Investors Await Earnings Reports
- Market Dynamics: U.S. stock futures fell on Monday, with major benchmark indices lower, reflecting investor caution ahead of earnings reports from companies like UnitedHealth, General Motors, and Microsoft.
- Earnings Expectations: Baker Hughes Co. rose 3.74% in premarket trading after reporting adjusted earnings of $0.78 per share for Q4, surpassing market estimates of $0.67, indicating strong performance in the energy sector.
- Stock Focus: Sarepta Therapeutics saw a 6.72% increase in its stock price after announcing the completion of its confirmatory trial commitment for ultra-rare disease PMO therapies, suggesting positive advancements in the biopharmaceutical field that may attract more investor interest.
- Economic Data Watch: Investors will closely monitor the Federal Reserve's interest rate decision this week, with markets pricing in a 97.2% likelihood of maintaining current rates, which could significantly impact both the stock and bond markets.
See More
